Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Treatment
3.2. Market snippet by Drug Class
3.3. Market snippet by Route of Administration
3.4. Market Snippet by Distribution Channel
3.5. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Hospital Acquired Infections (HAIs)
4.1.1.2. Growing Investment in Drug Discovery for Pseudomonas Aeruginosa
4.1.1.3. XX
4.1.2. Restraints:
4.1.2.1. Drug Resistance Ability of Pseudomonas Aeruginosa
4.1.2.2. XX
4.2. Opportunity
4.3. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Epidemiology
5.3. Pipeline Analysis
5.4. Supply Chain Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Unmet Needs
5.8. COVID-19 Impact Analysis
6. By Treatment
6.1. Introduction
6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Segment
6.3. Market Attractiveness Index, By Treatment Segment
6.3.1. Monotherapy*
6.3.1.1. Introduction
6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
6.3.2. Combination Therapy
7. By Drug Class
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
7.3. Market Attractiveness Index, By Drug Class Segment
7.3.1. Aminoglycoside*
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.2. Monobactam
7.3.3. Carbapenem
7.3.4. Cephalosporin
7.3.5. Others
8. By Route of Administration
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
8.3. Market Attractiveness Index, By Route of Administration Segment
8.3.1. Nasal*
8.3.1.1. Introduction
8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3.2. Oral
8.3.3. Intravenous
9. By Distribution Channel
9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
9.3. Market Attractiveness Index, By Distribution Channel Segment
9.3.1. Hospital Pharmacies*
9.3.1.1. Introduction
9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.3.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Italy
10.3.7.5. Spain
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. Australia
10.5.7.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Teva Pharmaceutical Industries Ltd.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. AbbVie Inc. (Allergan plc)
12.3. Pfizer, Inc.
12.4. Merck & Co., Inc.
12.5. AstraZeneca
12.6. Bristol-Myers Squibb Co.
12.7. Lupin Pharmaceuticals, Inc.
12.8. Janssen Pharmaceuticals, Inc.
12.9. Gilead Sciences Inc.
12.10. Novartis AG (LIST NOT EXHAUSTIVE)
13. DataM Intelligence
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us